One of the top candidates in the top 10 pharma list every year
GlaxoSmithLine (GSK)
US $ 23 billion
One of the top candidates in the top 10 pharma list every year, GlaxoSmithKline (GSK) is a leading British pharmaceutical company that is always proud of a solid pipeline of innovative drugs. The company has specialized expertise in a wide range of therapy areas but is particularly successful in the areas of HIV / AIDS, respiratory and vaccine. The company enjoyed a 2% earnings growth over the 2017 figures, with sales of GSK being the highest-selling HIV drug in Trivicha, and Nuchala, a successful treatment for traumatic, asthma and COPD, and Elipetta inhalers, and asthma. Last year GSK saw the original approval of Shingrix developed for the treatment of the Shingrix virus, which was expected to be very successful in 2018, with sales reaching £ 784 million. In general, there was a slight increase in 2018 by steep generic competition for various GSK drugs such as Ceratid, Epizixm and Avodart.
US $ 23 billion
One of the top candidates in the top 10 pharma list every year, GlaxoSmithKline (GSK) is a leading British pharmaceutical company that is always proud of a solid pipeline of innovative drugs. The company has specialized expertise in a wide range of therapy areas but is particularly successful in the areas of HIV / AIDS, respiratory and vaccine. The company enjoyed a 2% earnings growth over the 2017 figures, with sales of GSK being the highest-selling HIV drug in Trivicha, and Nuchala, a successful treatment for traumatic, asthma and COPD, and Elipetta inhalers, and asthma. Last year GSK saw the original approval of Shingrix developed for the treatment of the Shingrix virus, which was expected to be very successful in 2018, with sales reaching £ 784 million. In general, there was a slight increase in 2018 by steep generic competition for various GSK drugs such as Ceratid, Epizixm and Avodart.
No comments